Author: Nishtha Mehrotra | EQMint

 

Synopsis: Park Medi World shares fell around 15% in two sessions amid concerns over a possible expansion of medicine trade-margin caps. Strong Q1 growth and broker targets offer context, but regulatory uncertainty and hospital expansion risks remain.

 

The Park Medi World share price (NSE: PARKHOSPS) fell about 9% on 13 October 2026 to around ₹231, according to the figures in the draft. The decline followed concerns over a Supreme Court hearing on medicine trade margins, which also affected hospital stocks.

 

The Court’s observations have raised questions about whether the existing 16% trade-margin cap on scheduled drugs could be extended to non-scheduled medicines. No final order extending the cap is established by the information provided.

 

Park Medi World has said the potential impact of price caps on cancer and chemotherapy drugs would be negligible. Cancer drugs reportedly account for less than 2% of its revenue, although a wider cap could have a greater effect.

 

The company’s Q1 FY27 revenue rose 19% to ₹475.7 crore, while net profit increased 42% to ₹82.51 crore. Management has guided for FY27 revenue of ₹2,080 crore.

 

Emkay and Choice Institutional Equities have reportedly set targets of ₹375 and ₹350, respectively. These are brokerage estimates, not guaranteed returns. Investors should 

also consider regulatory uncertainty, hospital ramp-up risks and valuation volatility.

 

Disclaimer: This article is for information purposes only and is not investment advice.

 

For more such information, visit EQMint

 

Join our WhatsApp channel for timely updates: Whatsapp